Schroders’s Alnylam Pharmaceuticals ALNY Stock Holding History

Schroders’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-510	Closed	-$74K	–	8
2022 Q2	$74K	Buy	+510	New	+$72.4K	0.02%	76

Other funds holding ALNY

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Schroders's ALNY Position: Q3 2022 in Review

Schroders sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 510 shares — an estimated $74K sold.

Schroders first reported a position in ALNY in Q2 2022 and held it in 1 quarter. The position peaked at $74K in Q2 2022. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

Schroders reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Schroders sold 510 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $74K.
Schroders first reported a position in Alnylam Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Schroders's Alnylam Pharmaceuticals position peaked at $74K in Q2 2022.
497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Schroders's 13F filing for Q3 2022, filed 24 Oct 2022.